Assenagon Asset Management S.A. Has $8.14 Million Stock Position in CryoPort, Inc. $CYRX

Assenagon Asset Management S.A. increased its stake in shares of CryoPort, Inc. (NASDAQ:CYRX) by 7.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,090,511 shares of the company’s stock after purchasing an additional 73,949 shares during the quarter. Assenagon Asset Management S.A. owned about 2.17% of CryoPort worth $8,135,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. SBI Securities Co. Ltd. increased its holdings in CryoPort by 548,750.0% in the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company’s stock valued at $67,000 after purchasing an additional 10,975 shares during the last quarter. CWM LLC lifted its stake in CryoPort by 1,437.0% in the first quarter. CWM LLC now owns 11,328 shares of the company’s stock valued at $69,000 after buying an additional 10,591 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of CryoPort by 4,434.6% in the first quarter. GAMMA Investing LLC now owns 14,556 shares of the company’s stock valued at $89,000 after buying an additional 14,235 shares during the period. ProShare Advisors LLC bought a new stake in shares of CryoPort during the fourth quarter worth $95,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in shares of CryoPort during the second quarter worth $123,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Stock Performance

Shares of CryoPort stock opened at $9.81 on Wednesday. The company’s 50 day moving average price is $8.52 and its two-hundred day moving average price is $7.09. The firm has a market capitalization of $491.19 million, a P/E ratio of 7.38 and a beta of 1.62. CryoPort, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $10.46. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.24 and a quick ratio of 15.47.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). The firm had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. On average, equities analysts forecast that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on CYRX shares. KeyCorp raised CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 target price on the stock in a research report on Wednesday, August 6th. Leerink Partners upgraded CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 target price on the stock in a report on Wednesday, August 6th. Stephens began coverage on shares of CryoPort in a report on Tuesday, July 22nd. They set an “overweight” rating and a $13.00 target price on the stock. Leerink Partnrs upgraded CryoPort from a “hold” rating to a “strong-buy” rating in a report on Wednesday, August 6th. Finally, BTIG Research increased their price target on CryoPort from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $12.56.

Insider Activity at CryoPort

In other CryoPort news, CFO Robert Stefanovich sold 9,300 shares of the company’s stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total value of $80,631.00. Following the sale, the chief financial officer owned 207,213 shares in the company, valued at approximately $1,796,536.71. The trade was a 4.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ramkumar Mandalam sold 40,728 shares of the company’s stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total transaction of $294,870.72. Following the completion of the sale, the director directly owned 92,328 shares in the company, valued at approximately $668,454.72. This represents a 30.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 80,028 shares of company stock worth $661,252 in the last quarter. 10.10% of the stock is owned by insiders.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.